​

HUTCHMED (China) (HCM) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

HCM Stock Forecast

HUTCHMED (China) (HCM) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $17.50, with a high of $17.50 and a low of $17.50. This represents a 19.29% increase from the last price of $14.67.

$14 $15 $16 $17 $18 $19 $20 High: $17.5 Avg: $17.5 Low: $17.5 Last Closed Price: $14.67

HCM Stock Rating

HUTCHMED (China) stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (80.00%), 1 Hold (10.00%), 1 Sell (10.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 1 8 Strong Sell Sell Hold Buy Strong Buy

HCM Price Target Upside V Benchmarks

TypeNameUpside
StockHUTCHMED (China)19.29%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks18.82%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$14.67$14.67$14.67
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 251921-13
Sep, 25193--13
Aug, 25193--13
Jul, 25193--13
Jun, 25293--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 14, 2024Jack LinMorgan Stanley$17.50$21.45-18.41%19.29%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 22, 2025Morgan StanleyOverweightUnderweightdowngrade
May 13, 2025HSBCBuyHolddowngrade
Aug 23, 2024Goldman SachsBuyBuyhold
May 29, 2024HSBCBuyinitialise
May 14, 2024Morgan StanleyOverweightOverweighthold
Nov 23, 2023Deutsche BankBuyupgrade
Nov 10, 2023Goldman SachsNeutralNeutralhold
Mar 02, 2023NeedhamBuyBuyhold
Aug 09, 2022Goldman SachsNeutralNeutralhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.28$-0.29$-0.48$0.59-----
Avg Forecast$-1.00$-1.64$-2.07$0.05$-0.04$0.19$0.62$1.42$2.53
High Forecast$-0.83$-1.36$-1.61$0.40$-0.02$0.43$0.73$1.66$2.97
Low Forecast$-1.17$-1.93$-2.54$-0.41$-0.06$0.01$0.53$1.22$2.18
Surprise %-72.00%-82.32%-76.81%1080.00%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$227.98M$356.13M$426.41M$838.00M-----
Avg Forecast$218.47M$340.63M$409.62M$806.40M$662.83M$804.77M$917.19M$1.11B$1.33B
High Forecast$248.00M$386.67M$480.42M$820.77M$712.32M$912.17M$1.04B$1.26B$1.51B
Low Forecast$189.65M$295.69M$338.77M$798.79M$585.98M$697.36M$818.29M$994.77M$1.19B
Surprise %4.35%4.55%4.10%3.92%-----

Net Income Forecast

$-2B $-1B $0 $1B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-194.56M$-227.66M$-410.14M$100.78M-----
Avg Forecast$-867.53M$-1.43B$-360.71M$-41.97M$-38.93M$103.33M$546.68M$1.25B$2.20B
High Forecast$-718.75M$-1.18B$-279.61M$345.44M$-15.57M$371.49M$631.24M$1.45B$2.58B
Low Forecast$-1.02B$-1.68B$-441.77M$-360.46M$-54.51M$7.05M$462.12M$1.06B$1.89B
Surprise %-77.57%-84.03%13.70%-340.12%-----

HCM Forecast FAQ

Is HUTCHMED (China) stock a buy?

HUTCHMED (China) stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that HUTCHMED (China) is a favorable investment for most analysts.

What is HUTCHMED (China)'s price target?

HUTCHMED (China)'s price target, set by 10 Wall Street analysts, averages $17.5 over the next 12 months. The price target range spans from $17.5 at the low end to $17.5 at the high end, suggesting a potential 19.29% change from the previous closing price of $14.67.

How does HUTCHMED (China) stock forecast compare to its benchmarks?

HUTCHMED (China)'s stock forecast shows a 19.29% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (18.82%).

What is the breakdown of analyst ratings for HUTCHMED (China) over the past three months?

  • October 2025: 7.69% Strong Buy, 69.23% Buy, 15.38% Hold, 7.69% Sell, 0% Strong Sell.
  • September 2025: 7.69% Strong Buy, 69.23% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 7.69% Strong Buy, 69.23% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.

What is HUTCHMED (China)’s EPS forecast?

HUTCHMED (China)'s average annual EPS forecast for its fiscal year ending in December 2024 is $-0.04, marking a -106.78% decrease from the reported $0.59 in 2023. Estimates for the following years are $0.19 in 2025, $0.62 in 2026, $1.42 in 2027, and $2.53 in 2028.

What is HUTCHMED (China)’s revenue forecast?

HUTCHMED (China)'s average annual revenue forecast for its fiscal year ending in December 2024 is $662.83M, reflecting a -20.90% decrease from the reported $838M in 2023. The forecast for 2025 is $804.77M, followed by $917.19M for 2026, $1.12B for 2027, and $1.33B for 2028.

What is HUTCHMED (China)’s net income forecast?

HUTCHMED (China)'s net income forecast for the fiscal year ending in December 2024 stands at $-38.934M, representing a -138.63% decrease from the reported $100.78M in 2023. Projections indicate $103.33M in 2025, $546.68M in 2026, $1.25B in 2027, and $2.2B in 2028.